Past, Present and Further Looking for Therapeutic Management of Pancreatic Ductal Adenocarcinoma (2nd Edition)

Dear Colleagues,

Pancreatic ductal adenocarcinoma (PDAC) still represents one of the cancers with the poorest prognosis. Currently, surgery remains the only curative treatment for PDAC, but the 5-year survival rate of resected patients is only about 20–25%. During the last decades, some improvements have been achieved in terms of chemotherapic treatment, with the development of specific multi-chemotherapic regimens (FOLFIRINOX, gemcitabine + nab-paclitaxel, PAX-G) that have improved oncological results if compared with historically adopted single chemotherapic agents (gemcitabine). Moreover, if historically, for resectable PDAC, the gold standard strategy was surgery followed by adjuvant therapy, currently the scenario is radically changing. More often, the idea is to perform neoadjuvant therapy followed by surgery and, eventually, adjuvant treatment. The rationale for this approach is the early management of micro-metastatic disease and to allow a better selection of patient candidates for surgery. Thus, the analyses of old, recent, and upcoming molecular markers could change the landscape of clinical management of the PDAC. However, preclinical models of PDAC, including all different levels of models approaching PDAC, will be appreciated in order to show experimental attempts to validate the role of biomolecular markers and their affinity for chemotherapy. Indeed, other new frontiers of PDAC treatment, including phytotherapy and theragnostic molecules, are welcome.

This Special Issue aims to evaluate all the novel therapeutic approaches for the management of PDAC (resectable, borderline-resectable, locally advanced, and metastatic disease). Pre-clinical and clinical studies focusing on this topic will be included in this Special Issue.

Dr. Gennaro Nappo
Dr. Niccola Funel
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• pancreatic cancer
• pancreatic ductal adenocarcinoma
• treatment pancreatic cancer
• chemotherapy pancreatic cancer
• radiotherapy pancreatic cancer
• pancreatic cancer biology
• PDAC preclinical model
• biomolecular markers
• theragnostic molecules
• target therapy

• Past, Present and Further Looking for Therapeutic Management of Pancreatic Ductal Adenocarcinoma in Biomedicines (5 articles)